Candel Therapeutics Inc (NASDAQ:CADL)’s traded shares stood at 1.22 million during the last session, with the company’s beta value hitting -1.20. At the close of trading, the stock’s price was $7.69, to imply a decrease of -3.87% or -$0.31 in intraday trading. The CADL share’s 52-week high remains $14.60, putting it -89.86% down since that peak but still an impressive 84.92% since price per share fell to its 52-week low of $1.16. The company has a valuation of $342.01M, with an average of 1.67 million shares in intraday trading volume over the past 10 days and average of 3.68 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Candel Therapeutics Inc (CADL), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CADL a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
After registering a -3.87% downside in the last session, Candel Therapeutics Inc (CADL) has traded red over the past five days. The 5-day price performance for the stock is -11.91%, and 13.93% over 30 days. With these gigs, the year-to-date price performance is -11.41%. Short interest in Candel Therapeutics Inc (NASDAQ:CADL) saw shorts transact 1.78 million shares and set a 7.72 days time to cover.
Candel Therapeutics Inc (CADL) estimates and forecasts
Looking at statistics comparing Candel Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Candel Therapeutics Inc (CADL) shares are 17.05% up over the last 6 months, with its year-to-date growth rate lower than industry average at -21.37% against 16.70%.
CADL Dividends
Candel Therapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
Candel Therapeutics Inc insiders hold 30.39% of total outstanding shares, with institutional holders owning 22.53% of the shares at 32.37% float percentage. In total, 22.53% institutions holds shares in the company, led by NORTHPOND VENTURES, LLC. As of 2024-06-30, the company held over 1.94 million shares (or 6.628% of shares), all amounting to roughly $12.0 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 0.82 million shares, or about 2.819% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $5.1 million.
We also have iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Candel Therapeutics Inc (CADL) shares. Going by data provided on Oct 31, 2024 , iShares Russell 2000 ETF holds roughly 511.78 shares. This is just over 1.58% of the total shares, with a market valuation of $3.94 million. Data from the same date shows that the other fund manager holds a little less at 453.81, or 1.40% of the shares, all valued at about 3.49 million.
